Axsome Therapeutics will unveil data demonstrating solriamfetol’s ability to enhance cognitive functioning in patients with OSA and narcolepsy at SLEEP 2024.


Summary: Axsome Therapeutics Inc will present five studies on solriamfetol at SLEEP 2024, including two featured oral plenary presentations, with data highlighting solriamfetol’s improvements in cognitive function for patients with obstructive sleep apnea (OSA) and narcolepsy. Solriamfetol (Sunosi) is approved for treating excessive daytime sleepiness in these conditions. The SHARP study showed enhanced executive function, memory, and processing speed in patients with OSA and EDS, emphasizing the cognitive benefits of solriamfetol.

Key Takeaways:

  • Axsome Therapeutics will showcase five studies on solriamfetol, including two featured oral plenary presentations, at SLEEP 2024.
  • The SHARP study demonstrated significant improvements in cognitive functions such as executive function, memory, and processing speed in patients with OSA and excessive daytime sleepiness.
  • Solriamfetol (Sunosi) is approved for treating excessive daytime sleepiness in patients with obstructive sleep apnea and narcolepsy.

Axsome Therapeutics Inc announced five presentations on solriamfetol at SLEEP 2024, including two featured oral plenary presentations, showcasing data that demonstrate improvements in cognitive function for patients with obstructive sleep apnea (OSA) or narcolepsy.

“Cognitive functioning is an underappreciated facet of sleep disorders. Often overshadowed by clinically defining symptoms such as EDS (excessive daytime sleepiness), impaired cognition involves significant burden to patient lives. The SHARP study of solriamfetol showed improved cognitive functioning in participants with impaired cognition associated with OSA and EDS,” says Hans Van Dongen, PhD, professor at Washington State University and presenting author of the SHARP study plenary lecture, in a release. “In addition, solriamfetol demonstrated improvements across measures of executive function, memory, and processing speed.”

Solriamfetol (brand name Sunosi, Axsome) is approved for patients with excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea.

Presentation Details for SLEEP 2024

Details for the presentations are as follows:

Title: Solriamfetol on cognition in obstructive sleep apnea with excessive daytime sleepiness and impaired cognition
Lead Author: Hans Van Dongen, PhD, professor at Washington State University
Plenary Session: O-09
Plenary Date/Time: Tuesday, June 4, from 9:15-9:30 am Central Time
Poster Session: P-45
Poster Number: 390
Poster Date/Time: Wednesday, June 5, from 11-11:45 am Central Time


Title: Effects of solriamfetol on cognition on patients with excessive daytime sleepiness associated with narcolepsy
Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
Plenary Session: O-18
Plenary Date/Time: Tuesday, June 4, from 5-5:15 pm Central Time
Poster Session: P-13
Poster Number: 266
Poster Date/Time: Monday, June 3, from 11-11:45 am Central Time


Title: Solriamfetol and maintenance of wakefulness outcomes in patients with narcolepsy and obstructive sleep apnea
Lead Author: Michael Thorpy, MB, ChB, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine
Poster Session: P-29
Poster Number: 324
Poster Date/Time: Tuesday, June 4, from 11-11:45 am Central Time


Title: Real-world use of solriamfetol for excessive daytime sleepiness in patients reporting anxiety or depression
Lead Author: Ulf Kallweit, assistant professor of Neurology at the University Witten/Herdecke, Germany.
Poster Session: P-39
Poster Number: 200
Poster Date/Time: Wednesday, June 5, from 11-11:45 am Central Time


Title: SURWEY: Treatment of excessive daytime sleepiness with solriamfetol: initiation, titration, and outcomes
Lead Author: Samantha Floam, DMD, Axsome Therapeutics
Poster Session: P-29
Poster Number: 325
Poster Date/Time: Tuesday, June 4, from 10-10:45 am Central Time

Photo 1563603 © Pavel Losevsky | Dreamstime.com